Mack Mabry
AbbVie
19 Papers
126 Citations
Mack Mabry is an academic researcher from AbbVie. The author has contributed to research in topics: Venetoclax & Navitoclax. The author has an hindex of 12, co-authored 19 publications. Previous affiliations of Mack Mabry include Abbott Laboratories.
Chat about Author
Papers
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva,Daniel A. Pollyea,Jalaja Potluri,Brenda Chyla,Leah Hogdal,Todd Busman,Evelyn McKeegan,Ahmed Salem,Ming Zhu,Justin L. Ricker,William Blum,Courtney D. DiNardo,Tapan M. Kadia,Martin Dunbar,Rachel Kirby,Nancy Falotico,Joel D. Leverson,Rod A. Humerickhouse,Mack Mabry,Richard Stone,Hagop M. Kantarjian,Anthony Letai +21 more
TL;DR: Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study.
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D. DiNardo,Keith W. Pratz,Anthony Letai,Brian A. Jonas,Andrew H. Wei,Michael J. Thirman,Martha Arellano,Mark G. Frattini,Hagop M. Kantarjian,Relja Popovic,Brenda Chyla,Tu Xu,Martin Dunbar,Suresh Agarwal,Rod A. Humerickhouse,Mack Mabry,Jalaja Potluri,Marina Konopleva,Daniel A. Pollyea +18 more
TL;DR: This combination phase 1b study enrolled previously untreated patients aged 65 years and over with acute myeloid leukaemia who were ineligible for standard induction therapy and suggested synergy between hypomethylating agents and venetoclax to determine the maximum tolerated dose and recommended phase 2 dose and analysed safety, pharmacokinetics, and anti-leukaemic activity in all patients.
654
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin,Christine L. Hann,Edward B. Garon,Moacyr Ribeiro de Oliveira,Philip Bonomi,D. Ross Camidge,Quincy Chu,Giuseppe Giaccone,Divis Khaira,Suresh S. Ramalingam,Malcolm R Ranson,Caroline Dive,Evelyn McKeegan,Brenda Chyla,Barry L. Dowell,Arunava Chakravartty,Cathy E. Nolan,Niki Rudersdorf,Todd A. Busman,Mack Mabry,Andrew Krivoshik,Rod A. Humerickhouse,Geoffrey I. Shapiro,Leena Gandhi +23 more
TL;DR: Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics and Correlative analyses suggest several putative biomarkers of clinical benefit.
540
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M. Cleary,Caio Max S. Rocha Lima,Herbert Hurwitz,Alberto J. Montero,Catherine Franklin,Jianning Yang,Alison M. Graham,Todd Busman,Mack Mabry,Kyle D. Holen,Geoffrey I. Shapiro,Geoffrey I. Shapiro,Hope E. Uronis +12 more
TL;DR: The combination of navitoclax 325 mg with gemcitabine 1,000 mg/m2 was generally well tolerated and exhibited a favorable safety profile in patients with advanced solid tumors.
75
A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
Courtney D. DiNardo,Daniel A. Pollyea,Keith W. Pratz,Michael J. Thirman,Anthony Letai,Mark G. Frattini,Brian A. Jonas,Joel D. Leverson,Ming Zhu,Martin Dunbar,Nancy Falotico,Rachel Kirby,Suresh Agarwal,Mack Mabry,Jalaja Potluri,Rod A. Humerickhouse,Hagop M. Kantarjian,Marina Konopleva +17 more
TL;DR: Dual primary objectives are safety and pharmacokinetic (PK) profile of VEN in combination with DEC or AZA in older (≥65 years) Tx-naive AML pts and preliminary efficacy evaluations.
67